Beijing Health Guard Biotechnology (BJSE:920575) Notes Receivable: ¥0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920575 Beijing Health Guard Biotechnology Inc BJSE:920575
47 GF Score
Price ¥5.59
GF Value ¥7.92
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Beijing Health Guard Biotechnology Notes Receivable?

Beijing Health Guard Biotechnology BJSE:920575 47 Notes Receivable is ¥0.00 Mil as of Jun. 2026. GuruFocus rates BJSE:920575 with a GF Score™ of 47/100 and a GF Value™ of ¥7.92 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Beijing Health Guard Biotechnology's Notes Receivable for the quarter that ended in Jun. 2026 was ¥0.00 Mil.

Beijing Health Guard Biotechnology Notes Receivable Related Terms

Beijing Health Guard Biotechnology Notes Receivable Historical Data

* Premium members only.

The historical data trend for Beijing Health Guard Biotechnology's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Health Guard Biotechnology Notes Receivable Chart

Beijing Health Guard Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beijing Health Guard Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BJSE:920575
47GF Score
Beijing Health Guard Biotechnology Inc BJSE:920575
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Health Guard Biotechnology Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0.00 Mil mean?
Beijing Health Guard Biotechnology (BJSE:920575) has a Notes Receivable of ¥0.00 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Health Guard Biotechnology and its competitors.
Is Beijing Health Guard Biotechnology's Notes Receivable too high?
Beijing Health Guard Biotechnology's current Notes Receivable is ¥0.00 Mil. Overall, Beijing Health Guard Biotechnology has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Health Guard Biotechnology's Notes Receivable compare to VRTX and REGN?
Beijing Health Guard Biotechnology's Notes Receivable of ¥0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Health Guard Biotechnology and its competitors. Beijing Health Guard Biotechnology's current Notes Receivable is ¥0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Health Guard Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Beijing Health Guard Biotechnology (BJSE:920575) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.92, compared to a current price of ¥5.59 — trading 29.4% below its estimated fair value. The current Notes Receivable is ¥0.00 Mil. Beijing Health Guard Biotechnology's overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Beijing Health Guard Biotechnology (BJSE:920575), the current Notes Receivable is ¥0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Health Guard Biotechnology (BJSE:920575) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Health Guard Biotechnology stock appears to be undervalued. The current stock price of ¥5.59 is trading 29.4% below its estimated GF Value™ of ¥7.92. GuruFocus considers Beijing Health Guard Biotechnology to be Modestly Undervalued.

Key valuation signals for BJSE:920575:

  • Notes Receivable: ¥0.00 Mil
  • GF Value™: ¥7.92 vs. price of ¥5.59 (29.4% below fair value)
  • GF Score™: 47/100 with 10 warning signs

No single metric tells the full story. See the BJSE:920575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Health Guard Biotechnology Business Description

Address No. 7 Rongchang East Street, Beijing Economic and Technological Development Zone, Room 201 and 202, Building A2, Beijing, CHN, 100176
Beijing Health Guard Biotechnology Inc engages in the research, development, and industrialization of recombinant protein vaccines. It mainly develops HPV vaccines in China and also advances multiple innovative candidate vaccines for other infectious diseases. Its core pipeline product includes a trivalent and a nonavalent HPV vaccine.
47GF Score

Get the complete analysis for BJSE:920575

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥5.59
Price
¥7.92
GF Value